Search
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalIt is used extensively as an antiviral or antineoplastic agent.
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPhenobarbital
go.drugbank.com/drugs/DB01174ApprovedInvestigationalA barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also i...
Mixtures: PB Hyos, Re-PB HyosCategories: P-glycoprotein inducers, P-glycoprotein substratesDotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawnGa-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.
Von Willebrand factor human
go.drugbank.com/drugs/DB13133ApprovedInvestigationalThe human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis.
Mixtures: HAEMATE P 1000/2400 IU I.V. ENJEKSİYON/İNFÜZYON İÇİN TOZ VE ÇÖZÜCÜ, HAEMATE P 500/1200 IU I.V. ENJEKSİYON/İNFÜZYON İÇİN TOZ VE ÇÖZÜCÜProducts: IMMUNATE 50 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, IMMUNATE 100 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTIONEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesCabamiquine
go.drugbank.com/drugs/DB21477InvestigationalCabamiquine has a monoisotopic molecular weight of 462.24 Da. … Cabamiquine is under investigation in clinical trial NCT05974267 (Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [A31965].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPF-03463275
go.drugbank.com/drugs/DB11993InvestigationalPF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.
Tinlorafenib
go.drugbank.com/drugs/DB17082InvestigationalTinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of BRAF V600 mutations.[A253992]